Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Shares Outstanding (Diluted Average) (2021 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $7.6 million as the latest value for Q1 2026.

  • Quarterly Shares Outstanding (Diluted Average) rose 9.46% to $7.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Jan 2026, up 9.46% year-over-year, with the annual reading at $7.3 million for FY2025, 23.5% down from the prior year.
  • Shares Outstanding (Diluted Average) for Q1 2026 was $7.6 million at PharmaCyte Biotech, up from $6.8 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $20.8 million in Q3 2022, with the low at $6.8 million in Q3 2025.
  • Average Shares Outstanding (Diluted Average) over 5 years is $11.8 million, with a median of $9.6 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Diluted Average) surged 1208.94% in 2022, then crashed 54.69% in 2024.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $20.6 million in 2022, then crashed by 48.1% to $10.7 million in 2023, then dropped by 28.52% to $7.6 million in 2024, then fell by 11.02% to $6.8 million in 2025, then increased by 12.1% to $7.6 million in 2026.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $7.6 million, $6.8 million, and $6.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.